{
    "nct_id": "NCT05590923",
    "official_title": "The Efficacy of Steroid-Sparing Anti-Emetic Therapy in Patients Treated With High or Moderate Emetogenic Chemotherapy; Single Center Non-Inferiority Open Label Randomized Controlled Trial",
    "inclusion_criteria": "* 18 years and older\n* confirmed cancer diagnosis\n* starting cycle 1 of an FDA approved treatment that is categorized as high-emetogenic (nausea and vomiting inducing) chemotherapy per National Comprehensive Cancer NetworkÂ® guidelines\n* Eastern Cooperative Oncology Group performance score of 0 or 1\n* appropriate renal function\n* appropriate hepatic function\n* appropriate hematologic function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients will be excluded if they experience nausea or vomiting up to 24 hours before chemotherapy,\n* currently on a glucocorticoid therapy\n* contraindication to glucocorticoid therapy\n* taking any medication that has antiemetic properties.\n* scheduled or planned to receive radiation within one week of or concurrently with chemotherapy\n* brain metastases.",
    "miscellaneous_criteria": ""
}